
News|Articles|June 6, 2005
New product newswire
From GlaxoSmithKline, Research Triangle Park, N.C., (919) 483-2100, comes Boostrix (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed [Tdap]). The product is indicated as a booster vaccine to be given as a single dose to patients aged 10 to 18. This booster adds a pertussis component to the tetanus/diphtheria booster routinely administered to teens.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Long-Term Adverse Effects After COVID-19 Vaccination Vary by Brand
2
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
3
Meta-Analysis Identifies 5 Risk Factors for Post-COVID-19 Condition
4
Individualized Approach Helps When Intensifying GLP-1 Therapy in T2D
5







































